-
公开(公告)号：EP4461308A2
公开(公告)日：2024-11-13
申请号：EP24202493.3
申请日：2013-07-12
IPC分类号： A61K39/00
摘要： The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
-
公开(公告)号：EP4019041A1
公开(公告)日：2022-06-29
申请号：EP21215762.2
申请日：2013-07-12
IPC分类号： A61K39/00
摘要： The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
-
公开(公告)号：EP4313084A1
公开(公告)日：2024-02-07
申请号：EP22776700.1
申请日：2022-03-25
发明人： JOHNSON, Lexus R. , MINN, Andy , JUNE, Carl H.
-
4.发明公开
公开(公告)号：EP4303229A2
公开(公告)日：2024-01-10
申请号：EP23193480.3
申请日：2015-01-21
IPC分类号： C07K14/705
摘要： The invention provides T cells comprising nucleic caid sequence encoding a chimeric antigen receptor and a nucleic acid sequenceencoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
-
公开(公告)号：EP4036109A2
公开(公告)日：2022-08-03
申请号：EP21209515.2
申请日：2015-12-28
发明人： BEDOYA, Felipe , GHASSEMI, Saba , JUNE, Carl H. , LEVINE, Bruce L. , MELENHORST, Jan J. , MILONE, Michael C. , POWELL, Daniel J. Jr. , ZHENG, Zoe
IPC分类号： C07K14/725 , C12N5/00 , C12N5/0783 , A61K39/00
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
公开(公告)号：EP3967709A1
公开(公告)日：2022-03-16
申请号：EP21183416.3
申请日：2015-09-17
发明人： ENGELS, Boris , IDAMAKANTI, Neeraja , JUNE, Carl H. , LOEW, Andreas , MILONE, Michael C. , ENGELS, Boris , WANG, Enxiu , WU, Qilong , BEATTY, Gregory
IPC分类号： C07K16/28 , C07K16/30 , C07K14/705 , C07K14/735 , A61P35/00 , A61P37/04 , A61P43/00
摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a "NKR-CAR" which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
-
公开(公告)号：EP3730512A1
公开(公告)日：2020-10-28
申请号：EP20164621.3
申请日：2013-07-12
发明人： JUNE, Carl H. , ZHAO, Yangbing , LIU, Xiaojun
摘要： The present invention provides a genetically modified T cell, i.e. genetically modified to express a chimeric antigen receptor (CAR), and a bispecific antibody. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof. The genetically modified T cell be used in methods for treating cancer in a human.
-
公开(公告)号：EP3174546B1
公开(公告)日：2019-10-30
申请号：EP15753252.4
申请日：2015-07-31
IPC分类号： C07K16/28 , A61K39/00 , A61K35/17 , C07K14/705 , A61K39/395 , A61K31/436 , C07K14/725 , C12N5/0783
-
9.发明公开
公开(公告)号：EP3340995A1
公开(公告)日：2018-07-04
申请号：EP16842710.2
申请日：2016-08-26
CPC分类号： A61K35/17 , A61K35/00 , A61K35/12 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.
-
公开(公告)号：EP3328402A1
公开(公告)日：2018-06-06
申请号：EP16831340.1
申请日：2016-07-28
发明人： GILL, Saar , KLICHINSKY, Michael , JUNE, Carl H.
CPC分类号： C07K14/70517 , A61K35/14 , A61K35/15 , A61K38/00 , A61K2039/505 , A61P35/00 , C07K14/7051 , C07K14/70535 , C07K14/7056 , C07K16/2803 , C07K16/30 , C07K16/32 , C07K19/00 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/74 , C12N5/0645 , C12N2510/00
摘要： The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.04 秒)
